James Pellissier
Overview
Explore the profile of James Pellissier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
274
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang M, Ramsey S, Xue W, Xie J, Pellissier J, Briggs A
Pharmacoeconomics
. 2021 Nov;
40(3):257-268.
PMID: 34841472
In this review, we summarize the challenges faced by existing oncology treatment sequence decision models and introduce a general framework to conceptualize such models. In the proposed framework, patients with...
2.
Loong H, Wong C, Leung L, Dhankhar P, Insinga R, Chandwani S, et al.
Pharmacoecon Open
. 2019 Sep;
4(2):235-247.
PMID: 31531842
Background: Pembrolizumab, a monoclonal antibody against programmed death ligand 1 (PD-L1), is approved by several regulatory agencies for first-line treatment of metastatic non-small-cell lung cancer (NSCLC) with a PD-L1 tumor...
3.
Patterson K, Prabhu V, Xu R, Li H, Meng Y, Zarabi N, et al.
Eur Urol Oncol
. 2019 Aug;
2(5):565-571.
PMID: 31412011
Background: There is an unmet need for effective therapies for patients with advanced or metastatic urothelial cancer who cannot tolerate cisplatin-based chemotherapy. Cisplatin-ineligible patients experience a high frequency of adverse...
4.
Huang M, Pietanza M, Samkari A, Pellissier J, Burke T, Chandwani S, et al.
Pharmacoeconomics
. 2018 Dec;
37(1):105-116.
PMID: 30515719
Objectives: Pembrolizumab monotherapy showed significantly longer overall survival and fewer treatment-related adverse events compared to chemotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with programmed death...
5.
Aprepitant for Patients Receiving Highly Emetogenic Chemotherapy: An Economic Analysis for Singapore
Lopes G, Burke T, Pellissier J, Zhang X, Dedhiya S, Chan A
Value Health Reg Issues
. 2018 Apr;
1(1):66-74.
PMID: 29702829
Background: Aprepitant (a neurokinin 1 receptor antagonist), in combination with a serotonin receptor antagonist (5-HT3 RA) and dexamethasone, has demonstrated superior efficacy on end points related to chemotherapy-induced nausea and...
6.
Miguel L, Vargas Lopes F, Pinheiro B, Wang J, Xu R, Pellissier J, et al.
Value Health
. 2017 Oct;
20(8):1065-1073.
PMID: 28964438
Background: The aim of this study was to assess the cost-effectiveness of pembrolizumab in treating patients with ipilimumab-naïve advanced melanoma in Portugal. Methods: A cost-effectiveness model was developed to analyze...
7.
Huang M, Lou Y, Pellissier J, Burke T, Liu F, Xu R, et al.
Pharmacoeconomics
. 2017 Jun;
35(8):831-844.
PMID: 28620848
Objectives: Our objectives were to evaluate the cost effectiveness of pembrolizumab compared with standard-of-care (SoC) platinum-based chemotherapy as first-line treatment in patients with metastatic non-small-cell lung cancer (NSCLC) that expresses...
8.
Wang J, Chmielowski B, Pellissier J, Xu R, Stevinson K, Liu F
J Manag Care Spec Pharm
. 2017 Jan;
23(2):184-194.
PMID: 28125365
Background: Recent clinical trials have shown that pembrolizumab significantly prolonged progression-free survival and overall survival compared with ipilimumab in ipilimumab-naïve patients with unresectable or metastatic melanoma. However, there has been...
9.
Huang M, Lou Y, Pellissier J, Burke T, Liu F, Xu R, et al.
J Med Econ
. 2016 Aug;
20(2):140-150.
PMID: 27571538
Objectives: This analysis aimed to evaluate the cost-effectiveness of pembrolizumab compared with docetaxel in patients with previously treated advanced non-squamous cell lung cancer (NSCLC) with PD-L1 positive tumors (total proportion...
10.
Chan S, Jen J, Burke T, Pellissier J
Asia Pac J Clin Oncol
. 2014 Feb;
10(1):80-91.
PMID: 24571059
Aim: We aim to evaluate the cost effectiveness of aprepitant-containing regimens for the prevention of chemotherapy-induced nausea and vomiting (CINV) among patients receiving high emetogenic chemotherapy (HEC) in Hong Kong....